Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect: European Urology

F Pederzoli, M Bandini, A Briganti, ER Plimack, G Niegisch, EY Yu, A Bamias, N Agarwal, SS Sridhar, CN Sternberg, UN Vaishampayan, C Théodore, JE Rosenberg, LC Harshman, J Bellmunt, MD Galsky, A Gallina, A Salonia, F Montorsi, A Necchion behalf of the RISC Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

Adjuvant chemotherapy after neoadjuvant treatment and radical cystectomy for muscle-invasive bladder cancer should be offered only to patients with a high risk of 1-yr recurrence. Time-based endpoints may be more useful to help data interpretation for the next adjuvant and neoadjuvant immunotherapy studies. © 2019 European Association of Urology
Original languageEnglish
Pages (from-to)425-429
Number of pages5
JournalEuropean Urology
Volume76
Issue number4
DOIs
Publication statusPublished - 2019

Fingerprint

Dive into the research topics of 'Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect: European Urology'. Together they form a unique fingerprint.

Cite this